According to a new report, published by KBV research, The Global Ulcerative Colitis Market size is expected to reach $9 billion by 2028, rising at a market growth of 5.7% CAGR during the forecast period.
The Biologics segment is showcasing a CAGR of 7.5% during (2022 - 2028). People prefer biologics to other medications because they act selectively rather than having a broad influence on the body; as a result, people prefer biologics to other medicines. The ability of biologics to function selectively rather than affecting the entire body, resulting in fewer medication-related adverse effects and increased preference among care providers and patients, contributes to the growth of the segment.
The Mild segment acquired maximum revenue share in the Global Ulcerative Colitis Market by Disease Type in 2021; thereby, achieving a market value of $4.5 billion by 2028. This is because of a rise in the number of inflammatory bowel diseases, ulcerative colitis incidences, and demand for ulcerative colitis treatment. Moreover, due to an increase in the frequency of ulcerative proctitis and the development of new ulcerative colitis medications in clinical laboratories, the moderate UC market is predicted to grow significantly throughout the projection period.
The Injectables segment has shown growth rate of 6.4% during (2022 - 2028). The fact that key pharmaceuticals for treating the condition, such as Biologics, are provided in this form accounts for the Injectable segment's market share. Furthermore, when drugs are supplied as injectables, they act in a selective and precise manner, resulting in their widespread use among healthcare providers. Moreover, an increase in the number of ulcerative colitis cases and a rise in the number of important players in the medical device sector developing novel medications would further drive the growth of the segment over the forecast years.
North America is the fastest growing region in the Global Ulcerative Colitis Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3.4 billion by 2028. The Europe market is estimated to witness a CAGR of 5.2% during (2022 - 2028). Additionally, The Asia Pacific market would exhibit a CAGR of 6.4% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/ulcerative-colitis-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
ByMolecule Type
By Disease Type
By Route of Administration
By Geography
Companies Profiled
Unique Offerings 
